Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MATINAS BIOPHARMA HOLDINGS, INC.

(MTNB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Matinas Biopharma Holdings, Inc. Announces Resignation of Patrick Le Pore as Director

09/17/2021 | 05:20pm EDT

Matinas BioPharma Holdings, Inc. announced that at the Annual Meeting, seven directors are to be elected. Patrick Le Pore is not standing for reelection. All directors of the Company will hold office until the next Annual Meeting of Stockholders or until their respective successors are duly elected and qualified or their earlier resignation or removal.


© S&P Capital IQ 2021
All news about MATINAS BIOPHARMA HOLDINGS, INC.
10/21MATINAS BIOPHARMA : Doses First Patient in Phase 1 Study of Antibiotic Drug Candidate
MT
10/21Matinas BioPharma Initiates Dosing in Phase 1 Study of Potential First Oral Aminoglycos..
GL
10/21MATINAS BIOPHARMA : Initiates Dosing in Phase 1 Study of Potential First Oral Aminoglycosi..
GL
10/21Matinas BioPharma Initiates Dosing in Phase 1 Study of Potential First Oral Aminoglycos..
CI
09/20MATINAS BIOPHARMA : Announces Accomplished Biotechnology Executive and Drug Developer Kath..
PU
09/20MATINAS BIOPHARMA HOLDINGS, INC. : Change in Directors or Principal Officers, Regulation F..
AQ
09/20MATINAS BIOPHARMA : Announces Accomplished Biotechnology Executive and Drug Developer Kath..
AQ
09/17Matinas Biopharma Holdings, Inc. Announces Resignation of Patrick Le Pore as Director
CI
09/14Matinas BioPharma Announces Webcast of Presentation at the H.C. Wainwright Global Inves..
GL
09/13MATINAS BIOPHARMA : Says MAT2203 Exceeds Primary Endpoint Threshold of Fungal Clearance in..
MT
More news
Analyst Recommendations on MATINAS BIOPHARMA HOLDINGS, INC.
More recommendations
Financials (USD)
Sales 2021 1,88 M - -
Net income 2021 -18,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -11,3x
Yield 2021 -
Capitalization 244 M 244 M -
Capi. / Sales 2021 130x
Capi. / Sales 2022 15,6x
Nbr of Employees 20
Free-Float 96,0%
Chart MATINAS BIOPHARMA HOLDINGS, INC.
Duration : Period :
Matinas BioPharma Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 1,13 $
Average target price 2,75 $
Spread / Average Target 143%
EPS Revisions
Managers and Directors
Jerome D. Jabbour President, Chief Executive Officer & Director
Keith A. Kucinski Chief Financial Officer
Herbert J. Conrad Chairman
Raphael J. Mannino Chief Scientific Officer & Senior Vice President
James J. Ferguson Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
MATINAS BIOPHARMA HOLDINGS, INC.-16.91%244
MODERNA, INC.212.57%131 807
LONZA GROUP AG32.74%61 177
IQVIA HOLDINGS INC.43.38%49 076
SEAGEN INC.-2.12%31 189
CELLTRION, INC.-38.86%25 455